PMID- 38048019
OWN - NLM
STAT- MEDLINE
DCOM- 20240206
LR  - 20240314
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Linking)
VI  - 41
IP  - 2
DP  - 2024 Feb
TI  - Efficacy and Safety of Disitamab Vedotin Combined with Programmed Death-1 
      Inhibitor for Advanced Urothelial Cancer: A Case-Series Study.
PG  - 857-866
LID - 10.1007/s12325-023-02729-1 [doi]
AB  - INTRODUCTION: Antibody-drug conjugate (ADC) and programmed death-1 (PD-1) 
      inhibitors play crucial roles in the treatment of advanced urothelial cancer 
      (aUC). Increasingly, combination treatment modalities are used in patients with 
      aUC intolerant to platinum-based chemotherapy (PBC). However, clinical evidence 
      on the efficacy and safety of disitamab vedotin plus PD-1 inhibitors for aUC is 
      limited. This case series aims to address this knowledge gap. METHODS: Patients 
      with aUC who were refractory or intolerant to PBC were included. All patients 
      received combined treatment with disitamab vedotin (one of the ADC drugs) and 
      PD-1 inhibitors for at least three cycles. The clinical characteristics of 
      examination, histopathology, outcomes, and adverse events (AEs) were 
      retrospectively collected. RESULTS: Among this case series, eight patients 
      received disitamab vedotin plus PD-1 inhibitors, of which three achieved a 
      complete response (CR) and two had a partial response (PR). The most common AE 
      was peripheral neuropathy (4/8); the remaining AEs were mostly of mild to 
      moderate severity or unknown and were manageable by supportive care. CONCLUSIONS: 
      Disitamab vedotin combined with PD-1 inhibitors exhibits a favorable efficacy and 
      safety profile, but subsequent larger cohort clinical studies are required to 
      provide evidence-based medicine for the universal application of this regimen.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Healthcare Ltd., part 
      of Springer Nature.
FAU - Zhao, Hongfan
AU  - Zhao H
AD  - Department of Urology, Xijing Hospital, The Fourth Military Medical University, 
      127 Changle West Road, Xi'an, 710032, Shaanxi, China.
FAU - Xu, Zhicheng
AU  - Xu Z
AD  - Department of Urology, Xijing Hospital, The Fourth Military Medical University, 
      127 Changle West Road, Xi'an, 710032, Shaanxi, China.
FAU - Li, Chengbin
AU  - Li C
AD  - Department of Urology, Xijing Hospital, The Fourth Military Medical University, 
      127 Changle West Road, Xi'an, 710032, Shaanxi, China.
FAU - Xu, Tong
AU  - Xu T
AD  - Department of Urology, Xijing Hospital, The Fourth Military Medical University, 
      127 Changle West Road, Xi'an, 710032, Shaanxi, China.
FAU - Zhang, Jingliang
AU  - Zhang J
AD  - Department of Urology, Xijing Hospital, The Fourth Military Medical University, 
      127 Changle West Road, Xi'an, 710032, Shaanxi, China.
FAU - Jiao, Jianhua
AU  - Jiao J
AD  - Department of Urology, Xijing Hospital, The Fourth Military Medical University, 
      127 Changle West Road, Xi'an, 710032, Shaanxi, China.
FAU - Yang, Bo
AU  - Yang B
AD  - Department of Urology, Xijing Hospital, The Fourth Military Medical University, 
      127 Changle West Road, Xi'an, 710032, Shaanxi, China.
FAU - Qin, Rongliang
AU  - Qin R
AD  - Department of Urology, Xijing Hospital, The Fourth Military Medical University, 
      127 Changle West Road, Xi'an, 710032, Shaanxi, China.
FAU - Yang, Lijun
AU  - Yang L
AD  - Department of Urology, Xijing Hospital, The Fourth Military Medical University, 
      127 Changle West Road, Xi'an, 710032, Shaanxi, China.
FAU - Qin, Weijun
AU  - Qin W
AD  - Department of Urology, Xijing Hospital, The Fourth Military Medical University, 
      127 Changle West Road, Xi'an, 710032, Shaanxi, China.
FAU - Jing, Yuming
AU  - Jing Y
AD  - Department of Urology, Xijing Hospital, The Fourth Military Medical University, 
      127 Changle West Road, Xi'an, 710032, Shaanxi, China. 349156663@qq.com.
LA  - eng
PT  - Journal Article
DEP - 20231204
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (disitamab vedotin)
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Oligopeptides)
MH  - Humans
MH  - *Immune Checkpoint Inhibitors/therapeutic use
MH  - Retrospective Studies
MH  - Antibodies, Monoclonal/therapeutic use
MH  - *Carcinoma, Transitional Cell/drug therapy
MH  - *Oligopeptides
OTO - NOTNLM
OT  - Advanced urothelial cancer
OT  - Antibody-drug conjugate
OT  - Case series
OT  - Programmed death-1
EDAT- 2023/12/04 12:41
MHDA- 2024/02/06 06:42
CRDT- 2023/12/04 11:10
PHST- 2023/09/13 00:00 [received]
PHST- 2023/11/01 00:00 [accepted]
PHST- 2024/02/06 06:42 [medline]
PHST- 2023/12/04 12:41 [pubmed]
PHST- 2023/12/04 11:10 [entrez]
AID - 10.1007/s12325-023-02729-1 [pii]
AID - 10.1007/s12325-023-02729-1 [doi]
PST - ppublish
SO  - Adv Ther. 2024 Feb;41(2):857-866. doi: 10.1007/s12325-023-02729-1. Epub 2023 Dec 
      4.